Clinical results of If current inhibition by ivabradine

Drugs

Volumn 67, Issue SUPPL. 2, 2007, Pages 35-41

  Tardif, Jean Claude ^a,b  

^a MONTREAL HEART INSTITUTE   (Canada)

^b UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

Heart rate; Ivabradine, therapeutic use; Research and development

Indexed keywords

ACETYLSALICYLIC ACID; AMLODIPINE; ANTIANGINA PECTORIS AGENT; ANTILIPEMIC AGENT; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CLOPIDOGREL; DIHYDROPYRIDINE; EZETIMIBE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IVABRADINE; NITRATE; VERAPAMIL;

BRADYCARDIA; CARDIAC PATIENT; CLINICAL STUDY; CLINICAL TRIAL; CORONARY ARTERY DISEASE; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FOLLOW UP; HEALTH PROGRAM; HEART FAILURE; HEART MUSCLE CONTRACTILITY; HEART RATE; HUMAN; ION CURRENT; MORBIDITY; MORTALITY; REVIEW; STABLE ANGINA PECTORIS; VISUAL DISORDER;

ANGINA;

EID: 36148951151     PISSN: 00126667     EISSN: 00126667     Source Type: Journal    
DOI: 10.2165/00003495-200767002-00005     Document Type: Review

References (35)

1. Elveback LR, Connolly DC, Melton LJ. Coronary heart disease in residents of Rochester, Minnesota: incidence 1950 through 1982. Mayo Clin Proc 1986; 61: 896-900
2. European Society of Cardiology. Management of stable angina pectoris: recommendations of the Task Force of the European Society of Cardiology. Eur Heart J 1997; 18: 394-413
3. Gibbons RJ, Chatterjee K, Daley J, et al. ACC/AHA/ACP-ASIM guidelines for the management of patients with chronic stable angina: executive summary and recommendations. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Patients with Chronic Stable Angina). Circulation 1999; 99: 2829-48
4. Andrews TC, Fenton T, Toyosaki N, et al. Subsets of ambulatory myocardial ischemia based on heart rate activity: circadian distribution and response to anti-ischemic medication. The Angina and Silent Ischemia Study Group (ASIS). Circulation 1993; 88: 92-100
5. Diaz A, Bourassa MG, Guertin MC, et al. Long-term prognostic value of resting heart rate in patients with suspected or proven coronary artery disease. Eur Heart J 2005; 26: 967-74
6. Jouven X, Empana JP, Schwartz PJ, et al. Heart-rate profile during exercise as a predictor of sudden death. N Engl J Med 2005; 352: 1951-8
7. Cucherat M. Relationship between heart rate lowering and benefits on cardiac and sudden death observed with beta-blockers in post MI patients: a meta-regression of randomized clinical trials [abstract 3633]. Eur Heart J 2006; 27 Suppl.: 590
8. Palatini P, Thijs L, Staessen JA, et al., for the Systolic Hypertension in Europe (Syst-Eur) Trial Investigators. Predictive value of clinic and ambulatory heart rate for mortality in elderly subjects with systolic hypertension. Arch Intern Med 2002; 162: 2313-21
9. Braunwald E. Heart disease: a textbook of cardiovascular medicine. 3rd ed. Philadelphia (PA): W.B. Saunders, 1988: 1330
10. Frishman WH, Sica DA. Calcium channel blockers. In: Frishman WH, Sonnenblick EH, Sica DA, editors. Cardiovascular pharmacotherapies. 2nd ed. New York: McGraw-Hill, 2003: 105-30
11. DiFrancesco D. Characterization of single pacemaker channels in cardiac sino-atrial node cells. Nature 1986; 324: 470-3
12. DiFrancesco D. The contribution of the 'pacemaker' current (If) to generation of spontaneous activity in rabbit sino-atrial node myocytes. J Physiol 1991; 34: 23-40
13. Borer JS, Fox K, Jaillon P, et al. Antianginal and antiischemic effects of ivabradine, an I(f) inhibitor, in stable angina: a randomized, double-blinded, multicentered, placebo-controlled trial. Circulation 2003; 107: 817-23
14. Savelieva I, Borer JS, Camm J. Low Incidence of significant bradycardia during therapy with an If current inhibitor ivabradine: heart rate reduction depends on baseline heart rate [abstract 1007-195]. J Am Coll Cardiol 2007; 49 (3 Suppl. A): 9
15. f inhibitor, compared with atenolol in patients with chronic stable angina. Eur Heart J 2005; 26: 2529-36
16. Simon L, Ghaleh B, Puybasset L, et al. Coronary and haemodynamic effects of S 16257, a new bradycardic agent, in resting and exercising conscious dogs. J Pharmacol Exp Ther 1995; 275: 659-66
17. Ruzyllo W, Tendera M, Ford I, et al. Antianginal efficacy and safety of ivabradine compared with amlodipine in patients with stable effort angina pectoris: a 3-month randomised, double-blind, multicentre, noninferiority trial. Drugs 2007; 67: 393-405
18. Lopez-Bescos L, Filipova S, Martos R. Long-term safety and efficacy of ivabradine in patients with chronic stable angina. Cardiology 2007 Sep 21; 108 (4): 387-96
19. f current blocker ivabradine on ventricular repolarization: analysis based on a population heart rate correction formula [abstract no. 1023-272]. J Am Coll Cardiol 2005; 45 Suppl.: 95A
20. Beere PA, Glagov S, Zarina CK. Retarding effect of lowered heart rate on coronary atherosclerosis. Science 1984; 226: 180-2
21. Perski A, Hamstein A, Lindvall K, et al. Heart rate correlates with severity of coronary atherosclerosis in young postinfarction patients. Am Heart J 1988; 116: 1369-73
22. Sutton Tyrrell K, Alcon HG, Wolfson Jr SK, et al. Predictors of carotid stenosis in older adults with and without isolated systolic hypertension. Stroke 1993; 24: 355-61
23. Heidland UE, Strauer BE. Left ventricular muscle mass and elevated heart rate are associated with coronary plaque disruption. Circulation 2001; 104: 1477-82
24. Benetos A, Rudnichi A, Homas F, et al. Influence of heart rate on mortality in a French population: role of age, gender and blood pressure. Hypertension 1999; 33: 44-52
25. Menotti A, Mulder I, Nissinen A, et al. Prevalence of morbidity and multimorbidity in elderly male populations and their impact on 10-year all-cause mortality: the FINE study (Finland, Italy, Netherlands, Elderly). J Clin Epidemiol 2001; 54: 680-6
26. Kjekshus J. Importance of heart rate in determining β-blocker efficacy in acute and long-term acute myocardial infarction intervention trials. Am J Cardiol 1986; 57: 43F-9F
27. Kjekshus J, Gukkestad L. Heart rate as therapeutic target in heart failure. Eur Heart J 1999; 1 Suppl. H: H64-9
28. Thackray SD, Ghosh JM, Wright GA, et al. The effect of altering heart rate on ventricular function in patients with heart failure treated with beta-blockers. Am Heart J 2006; 152 (4): 713.e9-13
29. Fox K, Ferrari R, Tendera M, et al., on behalf of the BEAUTIfUL Steering Committee. Rationale and design of a randomized, double-blind, placebo-controlled trial of ivabradine in patients with stable coronary artery disease and left ventricular systolic dysfunction: the morBidity-mortality EvAlUaTion of the I(f) inhibitor ivabradine in patients with coronary disease and left ventricULar dysfunction (BEAUTIfUL) study. Am Heart J 2006; 152: 860-6
30. Jondeau G, Korewicki J, Vasiliauskns D. Effect of ivabradine in patients with left ventricular systolic dysfunction and coronary artery disease [abstract 2637]. Eur Heart J 2004; 25 Suppl.: 451
31. Savelieva I, Le Heuzey JY, Jern S, et al. Heart rate variability is significantly increased by ivabradine compared with amlodipine in patients with chronic stable angina: a prospective randomized double-blind controlled study [abstract 908-242]. J Am Coll Cardiol 2007; 49 Suppl. A: 9
32. Lombardi F. Clinical implications of present physiological understanding of HRV components. Card Electrophysiol Rev 2002; 6: 245-9
33. Babu S, Holgate ST, Gadzik F. Absence of respiratory effects in asthmatic subjects with the If inhibitor ivabradine, a novel anti-anginal agent [abstract]. Eur Resp J 2006; 28 Suppl.: 50
34. Borer J. Clinical efficacy and biological tolerability of the If inhibitor ivabradine in diabetic patients with chronic stable angina [abstract no. P2096]. Eur Heart J 2006; 27 Suppl. 1: 329
35. European Society of Cardiology. Guidelines on the management of stable angina pectoris: executive summary. The Task Force on the Management of Stable Angina Pectoris of the European Society of Cardiology. Eur Heart J 2006; 27: 1341-81